Gilead Sciences (GILD) Land & Improvements (2010 - 2011)
Gilead Sciences posted quarterly Land & Improvements of $149.4 million for Q4 2011, up 8.39% year-on-year from $137.8 million in Q4 2010, and up 8.39% on a QoQ basis from $137.8 million in Q4 2010.
Gilead Sciences (GILD) has 2 years of Land & Improvements data on file, last reported at $149.4 million in Q4 2011.
- For the quarter ending Q4 2011, Land & Improvements rose 8.39% year-over-year to $149.4 million; the trailing twelve-month figure through Dec 2011 stood at $149.4 million (up 8.39% YoY), and the FY2011 full-year result was $149.4 million, up 8.39% from the prior year.
- Land & Improvements for Q4 2011 stood at $149.4 million, up from $137.8 million in the prior quarter.
- Across five years, Land & Improvements topped out at $149.4 million in Q4 2011 and bottomed at $137.8 million in Q4 2010.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Land & Improvements (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | - |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | - |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | - |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | - |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 157.00 Mn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2011 | 149.38 Mn |
| Dec 31, 2010 | 137.81 Mn |